Background
NCT number | Anti-Tim-3 agents | Combining agent | Mechanism of combining agents | Patients | Diseases | Phases |
---|---|---|---|---|---|---|
03489343 | Sym023 | – | – | 48 | Metastatic cancer Solid tumor Lymphoma | Phase 1 |
02817633 | TSR-022 | – | – | 627 | Advanced or metastatic solid tumors | Phase 1 |
02608268 | MBG453 | PDR001 | Anti-PD-1 | 250 | Advanced or metastatic solid tumors | Phase 1 and 2 |
03066648 | MBG453 | PDR001, Decitabine | Anti-PD-1, inhibit DNA methyltransferase | 70 | Leukemia Leukemia, myeloid Leukemia, myeloid, acute Myelodysplastic syndromes Preleukemia Bone marrow diseases Hematologic diseases | Phase 1 |
03099109 | LY3321367 | LY3300054 | Anti-PD-1 | 172 | Solid tumor | Phase 1 |
Structure and functions of Tim-3
Gene structure and protein structure of Tim-3
Ligands and functions of Tim-3
Ligands | Location of Tim-3 | Functions |
---|---|---|
Gal-9 | CD8+ T cells | Dysfunction and apoptosis [76] |
Th1 cells | 1. Th1 cell death [12] 2. Expansion of granulocytic MDSCs and MDSC-mediated immunosuppression [72] | |
Treg | Cross-regulation between Th17 and Treg cells [93] | |
Monocytes | Reduced phagocytic activity and HLA-DR expression [46] | |
Macrophages | M2 polarization [15] | |
NK | Enhanced IFN-γ production [19] | |
PtdSer | Macrophages | Elimination of apoptosis cells and cross-presentation [17] |
DCs | Elimination of apoptosis cells and cross-presentation [17] | |
HMGB1 | CD8+ T cell | Prevent HMGB1-mediated T cell activation [94] |
DCs | Interfere with the recruitment of nucleic acids into DC endosomes [18] | |
CEACAM1 | T cells |
Tim-3 in HCC diagnosis and prognosis
Tim-3 polymorphisms and HCC
Tim-3 as a potential prognostic biomarker for HCC
Tim-3 in TIME and HCC cells
Tim-3 and TILs
Tim-3 and TAMs
Tim-3 and HCC cells
Regulation of Tim-3 expression
New approaches targeting Tim-3
Antibodies targeting Tim-3
Anti-Tim-3 agents | Combining agents | Mechanism of combining agents | Diseases | |
---|---|---|---|---|
Anti-Tim-3 monotherapy | RMT3-23 | – | – | Sarcoma, colon adenocarcinoma, fibrosarcoma [71] |
5D12 | – | – | Lymphoma [72] | |
Tim-3Apt | – | – | ||
Combination of anti-Tim-3 agents with other agents | RMT3–23 | Anti-PD-1 antibody (clone: 29F.1A12) | Anti-PD-1 | Lung cancer [66] |
RMT3–23 | RMP1-14 | Anti-PD-1 | Melanoma, colon carcinoma [66] | |
RMT3–23 | UC10-4F10 | Anti-CTLA-4 | Melanoma [66] | |
RMT3–23 | RMP1-14 and UC10-4F10 | Anti-PD-1 and anti-CTLA-4 | Melanoma [66] | |
mTim-3 hFc | Anti-PD-1 antibody (clone: MIH7) | Anti-PD-1 | Acute myelogenous leukemia (AML) [67] | |
Anti-TIM-3 antibody (clone: 8B.2C12) | cc1 | Anti-CEACAM1 | Colorectal cancer [13] | |
RMT3–23 | Therapeutic anti-CD137 (clone: lob12.3) | Agonistic anti-CD137 antibody | Ovarian cancer [74] | |
Tim-3Apt | RMP1-14 | Anti-PD-1 | Colon carcinoma [77] | |
Tim-3Apt | Anti-PDL1 antibody (clone: 10F.9G2) | Anti-PDL1 | Colon carcinoma [78] | |
Combination of anti-Tim-3 agents with SRS | RMT3-23 | SRS | Radiotherapy | Glioma [73] |
RMT3-23 | Anti-PD-1 antibody, SRS | Anti-PD-1, radiotherapy | Glioma [73] |